ReviewLung1990
The role of eosinophils in asthma.
Review in Lung, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- p-STAT6, PU.1, and NF-κB are involved in allergen-induced late-phase airway inflammation in asthma patients.BMC pulmonary medicine · 2015Article
- Selective inflammatory response induced by intratracheal and intravenous administration of poly-L-arginine in guinea pig lungs.Inflammation · 1999Article
- IL-4 induces neutrophilic maturation of HL-60 cells and activation of human peripheral blood neutrophils.Clinical and experimental immunology · 1995Article
- Future developments in the pharmacotherapy of lung disease.Pharmaceutisch weekblad. Scientific edition · 1992Review
- Morphology and density features of eosinophil leukocytes in eosinophilic pneumonia. A case report.The Clinical investigator · 1992Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During recent years it has become apparent that the eosinophil may represent a powerful effector cell in the pathogenesis of asthma, particularly in the late asthmatic response. It can be stimulated by a number of stimuli among which PAF appears to be one of the most effective. The eosinophil is a source for a variety of proinflammatory and toxic products with profound effect in the lungs and airways. These eosinophil products mimic some of the features of asthma and the strong association of the eosinophil with asthma has led to the suggestion that asthma would be better classified as "chronic desquamating eosinophilic bronchitis." Although the evidence known to date is persuasive many questions still remain unanswered and await further investigation. Future therapeutic approaches in asthma may aim at interrupting the mechanisms leading to eosinophil bronchial accumulation and activation.
Indexed as
Identifiers
2117155What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.